SEC Filing Analysis: RECURSION PHARMACEUTICALS, INC. (RXRX)

Executive Summary

• Trading Significance: Low
• Key Takeaway: The CEO conducted a small, pre-scheduled sale of company stock valued at approximately $208,400, representing a negligible fraction of the company's market capitalization and the insider's total holdings.
• Market Impact: Neutral, due to the small size of the transaction and its execution under a Rule 10b5-1 trading plan.

Company Information

Field	Value
Company	RECURSION PHARMACEUTICALS, INC.
Ticker Symbol	RXRX
CIK	0001601830
Industry	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)

Insider Information

Field	Value
Name	Gibson Christopher
CIK	0001856369
Title/Position	Chief Executive Officer
Relationship	Director, Officer

Transaction Details

This filing reported multiple transactions. The most economically relevant is the sale of Class A Common Stock.

Field	Value
Form Type	4
Transaction Date	2025-11-04
Transaction Code	S (Sale)
Security Type	Class A Common Stock
Shares Involved	40,000
Price Per Share	$5.21
Total Value	$208,400
Shares Owned After (Class A Direct)	954,229
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$208,400
% of Market Cap	0.0088%
Shares Transacted	40,000
% of Shares Outstanding	0.0094%
Post-Transaction Ownership (Class A Direct)	954,229 shares (0.22% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: With a market capitalization of $2.37 billion, this $208k sale is immaterial.
• Ownership Concentration: The sale represents a very small portion of the CEO's total holdings, which include over 5.8 million shares of Class A and Class B stock (directly and indirectly) post-transaction.
• Transaction Significance: The transaction's value and share count are well below the thresholds for moderate significance (<0.1% of market cap and <0.1% of shares outstanding).

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: The transaction is too small to influence market sentiment. Its execution under a pre-disclosed 10b5-1 plan further neutralizes its informational value, indicating it is for personal financial planning rather than a reflection of the company's outlook.

Volume & Sentiment

• Expected Volume Impact: Negligible. The transaction size is a minor fraction of typical daily trading volume.
• Sentiment Indicator: Neutral. This type of pre-planned, small-scale insider sale is routine and not indicative of a change in insider confidence.

Additional Context

Transaction Notes

• Special Circumstances: The sale was conducted pursuant to a Rule 10b5-1 trading plan adopted on May 12, 2025. The filing also included the conversion of 60,000 Class B shares into Class A shares and a gift of 20,000 Class A shares.